Head-To-Head Review: Aytu BioPharma (AYTU) vs. Its Rivals

Aytu BioPharma (NASDAQ:AYTU) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Aytu BioPharma to similar companies based on the strength of its earnings, institutional ownership, risk, valuation, profitability, analyst recommendations and dividends.

Institutional & Insider Ownership

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.1% of Aytu BioPharma shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Aytu BioPharma and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	2	0	2	0	2.00
Aytu BioPharma Competitors	7776	13772	25741	1037	2.41

Aytu BioPharma presently has a consensus price target of $14.50, indicating a potential upside of 701.10%. As a group, “Pharmaceuticals” companies have a potential upside of 24.77%. Given Aytu BioPharma’s higher probable upside, equities research analysts plainly believe Aytu BioPharma is more favorable than its rivals.

Earnings & Valuation

This table compares Aytu BioPharma and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aytu BioPharma	$57.57 million	-$14.25 million	-1.09
Aytu BioPharma Competitors	$4.34 billion	$3.17 billion	552.48

Aytu BioPharma’s rivals have higher revenue and earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Aytu BioPharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-24.76%	-56.54%	-13.14%
Aytu BioPharma Competitors	-2,379.48%	-219.92%	-15.47%

Risk and Volatility

Aytu BioPharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, Aytu BioPharma’s rivals have a beta of -3.81, indicating that their average stock price is 481% less volatile than the S&P 500.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on commercializing prescription medicines and other healthcare products. The company’s portfolio has primarily centered on treatments for attention-deficit/hyperactivity disorder (ADHD), along with select pediatric and primary-care products. Aytu’s ADHD products have included Adzenys XR-ODT, an extended-release orally disintegrating tablet containing amphetamine; Cotempla XR-ODT, an extended-release orally disintegrating tablet containing methylphenidate; and Evekeo, an amphetamine sulfate product.